Skip to main content
Compass Pathways: home
  • About us
        • About us

          Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.

        • About us
          • Our purpose
          • Our stories
          • Our values
          • Our approach
        • Our team
          • Executive Team
          • Board of Directors
        • Our stories

          Everyone has a story about how mental health has affected them or someone they know. Our people bring their stories, and a wide range of backgrounds and skills, to Compass.

          Read our stories
  • Our work
        • Our work

          We want to give people living with mental health challenges better options.

        • About psilocybin therapy
        • Pipeline
          • Treatment-resistant depression (TRD)
          • Post-traumatic stress disorder (PTSD)
          • Anorexia nervosa
          • Pipeline overview
          • Investigator-initiated studies
        • Therapist training
        • Preclinical research
          • Discovery Center
        • Digital technologies
          • Digital technology blog
        • Our publications and results
          • COMP360 psilocybin in healthy participants
          • COMP360 psilocybin treatment in TRD
          • COMP360 psilocybin treatment in TRD with antidepressants
          • Therapist training: Frontiers in Psychiatry
        • Partnerships and collaborations
          • Centres of Excellence
          • Partnerships
        • Our approach
          • Compassionate use policy
          • Animal welfare
        • phase II clinical trial of psilocybin therapy
        • News and views

          Read our latest news and updates.

          Read more
  • Join us
        • Join us

          We are united by our commitment to improving mental health.

        • Join us
          • Working at Compass
          • Careers
          • 60 seconds with ...
        • Our purpose

          Watch our purpose video to find out who we are and what defines us.

          Find out more about our purpose
  • News and views
        • News and views

          Our collective understanding of mental illness is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.

        • All news and views
          • Our perspectives
          • Our blog
          • Podcast
          • White Paper
        • Compass news archive
        • Digital technology blog
        • Find out how we use digital tools, including AI, software and mathematics, to better understand mental illness.

          Digital technology blog
  • Investors
        • Investors

          We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.

        • News & events
          • News releases
          • Events
          • Presentations
          • SEC filings & annual reports
          • Our annual review
        • Stock information
          • Stock quote & chart
          • Historical price lookup
          • Analyst Coverage
          • Split history
        • Corporate governance
          • Documents & charters
          • Executive Team
          • Board of directors
          • Committee composition
          • Annual general meeting
        • Investor resources
          • Shareholder privacy notice
          • FAQs
          • Email alerts and RSS feeds
          • IR contact
        • COMP360 psilocybin treatment in TRD

          We have completed the largest randomised, controlled, double-blind psilocybin treatment study ever done.

          Read more about COMP360 psilocybin treatment in TRD
  • Impact
        • Impact

          We are working to create positive impact by developing transformative therapies for those who are not helped by current treatments, by helping to build the mental health ecosystem of the future, and by acting responsibly as an organisation.

        • Impact
          • Transformative therapies
          • Mental health ecosystem
          • Responsible organisation
        • About us

          Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.

          Read more about us
  • LinkedIn
  • Youtube
  • Twitter
  • Accessibility
accessibility options
  • High Contrast
  • Greyscale
  • Negative Contrast
  • Readable
  • Reset
Contact us

Investigator-initiated studies

We are progressing research that has the potential to change mental health outcomes, especially for those who have not been helped by existing treatments.

To support this, we work in collaboration with select academic institutions and researchers around the world. We provide our cGMP (clinical Good Manufacturing Practice – the highest manufacturing grade) COMP360 psilocybin to researchers free of charge, in exchange for the right to use safety data. Researchers are expected to cover packaging and shipping costs with our logistics provider. For these investigator-initiated studies (IISs), we also provide support with regulatory submissions.

These IISs are signal-generating, exploratory studies looking at indications in areas of unmet need, including anorexia, bipolar disorder II, body dysmorphic disorder, chronic cluster headache, major depressive disorder, and severe treatment-resistant depression.

Our IIS programme is currently full and we will update this page when we are open for new applications.  If you have any questions in the meantime, please contact us at info@compasspathways.com.

logo of
logo of
logo of
logo of
logo of
logo of
logo of

Our therapist training programme has been designed by leading experts from the fields of psychology, psychiatry and psychedelic therapy research, and approved by the FDA for research purposes.

Discover more
  1. Home
  2. Our work
  3. Investigator-initiated studies
This website is hosted Green - checked by thegreenwebfoundation.org

This website is powered by renewable energy

Useful links
  • Contact us
  • About psilocybin therapy
  • About us
  • Join us
  • News and views
Follow us
  • LinkedIn
  • Youtube
  • Twitter

Sign up to receive the latest Compass news.

Subscribe
  • Unsolicited Information Policy
  • Terms
  • Privacy
  • myPathfinder privacy

Compass © 2023. All rights reserved. Made by GIG.

The press releases and articles contained in this section are provided for historical purposes only. The information contained in each press release and article is accurate only as of the date each press release and article was originally issued. Compass disavows any obligation to update the information contained in such press releases and articles after the date of their issuance.

You are now leaving Compass Pathways’ website.

Compass does not control and is not responsible for the content on the website you are about to visit. Compass is providing this link as a convenience, and this link does not imply Compass endorsement of any material on the website you are about to visit. Do you wish to continue?